Human iPSC Line (Episomal, PBMC) from Ace Therapeutics was derived from human mesenchymal stromal cells (MSCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.

Human Cord Blood-CD34+ Hematopoietic Stem Cell from Ace Therapeutics are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube and are cryogenically preserved.

CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

Human Bone Marrow CD133+ Stem/Progenitor Cells from Ace Therapeutics are isolated using positive immunomagnetic cell separation procedures from bone marrow. Capable of a high level of proliferation and a wide range of differentiation, transplantation of bone marrow CD133+ cell lines has been shown to not only induced multilineage human hematopoiesis through the CD34+ lineage but also induce regeneration of cell lines in vitro in multiple locations by differentiating into endothelial cells, neural cells, hepatocytes, osteoblasts, and myocytes, with the list of tissue types this cell can differentiate into gradually increasing.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.

Human Embryonic Hematopoietic Stem Cells (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cells are only guaranteed with the purchase of Ace Therapeutics‘s Media and Ace Therapeutics‘s Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC From Adipose Mesenchymal Stromal Cells from Ace Therapeutics are generated using an episomal reprogramming containing a proprietary mix of vectors, containing Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1. The cell line was validated for pluripotency based on colony morphology, alkaline phosphatase expression, and expression of SSEA-4.iPS colonies exhibit classical morphology and growth.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.

Human Mesenchymal Stem Cells from Placenta (hPSCs) from Ace Therapeutics are human mesenchymal stem cells (hMSC) isolated from placental tissue, specifically from amnion, decidua, or chorion villi. MSC have been shown to differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myocytes, and β-pancreatic islets cells. They can also transdifferentiate into neuronal cells and hepatocytes.